aBLA Filing Intelligence & Biosimilar Opportunity

Opdualag

Nivolumab And Relatlimab-Rmbw

Anticancer

Intravenous Solution

Approval Date

18-Mar-22

Data Exclusivity Expiry

18-Mar-26

Market Exclusivity Expiry

18-Mar-34

Commercial snapshot

Market performance & projections

Revenue ($M)

1185

CAGR (%)

0.0983

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1374

2027

1528

2028

1646

2029

1724

2030

1786

2031

1836

2032

1876

Molecule profile

Details & specifications

Molecule

Nivolumab And Relatlimab-Rmbw

Innovator

E.R. SQUIBB & SONS, L.L.C.

Dosage Form

Intravenous Solution

Strength

240 mg

Therapeutic Category

Anticancer

Usage

To treat unresectable or metastatic melanoma

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.